Abstract
Operating in the three sectors of Pharmaceuticals, Chemicals and Plastics,
Solvay is represented worldwide. This report provides a full review of the
company' s activities together with sales forecasts for key products to 2010.
Operating in the three sectors of Pharmaceuticals, Chemicals and Plastics,
Solvay is represented worldwide. Over 95 per cent of its sales come from
outside Belgium and 49 per cent from outside the European Union.
Current Growth Drivers
Following the acquisition of Fournier Pharma, Solvay' s flagship product and
principal growth driver is now fenofibrate, a treatment for lipidic disorders
which is sold as Tricor in the US and Lipanthyl elsewhere. It has already
achieved blockbuster status and life-cycle development should further increase
sales substantially. Dualtis, a fixed-dose combination of fenofibrate and
metformin was filed in the EU in July 2006 and if approved, it would be the
first product on the market that combines a lipid-lowering drug with an oral
antidiabetic in one tablet; Fournier is conducting Phase III trials with Zolip
(fenofibrate+statin) for dyslipidaemia (launch scheduled for 2010); and a
next-generation fenofibrate, HEXA/ABT335, is undergoing Phase III trials. As a
result, the Cardiometabolic therapeutic area is set to become the company' s
most significant in terms of sales.
Other growth drivers include: the male hormone product, Androgel, which has
been Solvay' s top-selling product for a number of years; the neuroscience
products, Marinol (dronabinol) and Serc (betahistine); the influenza vaccine,
Influvac; the pancreatic enzyme, Creon; and Teveten (eprosartan mesylate) for
hypertension.
Pipeline Analysis
Following the integration of Fournier Pharma, Solvay Pharmaceuticals is
selectively reorganising its portfolio, with Cardiometabolics and
Neurosciences as its new primary fields. In these areas it intends to sustain
and build on its market leadership, and obtain new products through
in-licensing and acquisitions.
View Cart
